FrancophonIA/ELRC3.0 huggingface dataset:
English: Immediately discard syringe and needle into an approved Sharps Container.
Estonian: Visake süstal ja nõel koheselt teravatele esemetele ettenähtud mahutisse.
English: An additional overfill is included in each vial to ensure that 125 micrograms of romiplostim can be delivered.
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 125 mikrogrammi romiplostiimi manustamise.
English: An additional overfill is included in each vial to ensure that 125 mcg of romiplostim can be delivered (see vial content table below).
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 125 µg romiplostiimi manustamise (vt allpool viaalide sisu tabelit).
English: Haematochezia Mouth haemorrhage Stomach discomfort Stomatitis
Estonian: Iiveldus Diarrõa Kõhuvalu Kõhukinnisus Düspepsia
English: • Nplate 250 micrograms powder for solution for injection should be reconstituted with 0.72 mL sterile water for injections, yielding a deliverable volume of 0.5 mL.
Estonian: • Nplate 250 mikrogrammi süstelahuse pulber tuleb lahustada 0,72 ml steriilse süsteveega, mille tulemuseks on manustatav maht 0,5 ml.
English: Nplate 125 micrograms powder for solution for injection should be reconstituted with 0.44 mL sterile water for injections, yielding a deliverable volume of 0.25 mL.
Estonian: Nplate 125 mikrogrammi süstelahuse pulber tuleb lahustada 0,44 ml steriilse süsteveega, mille tulemuseks on manustatav maht 0,25 ml.
English: Dose adjustment guidance based on platelet count
Estonian: Annuse kohandamine trombotsüütide arvu alusel
English: Patients should be closely monitored for a decrease in platelet count and medically managed to avoid bleeding upon discontinuation of treatment with romiplostim.
Estonian: Pärast ravi katkestamist romiplostiimiga on vaja tähelepanelikult jälgida trombotsüütide arvu vähenemist patsientidel ja veritsusi meditsiiniliselt vältida.
English: Romiplostim serum levels appear inversely related to platelet counts.
Estonian: Romiplostiimi tase seerumis oli pöördvõrdeline trombotsüütide hulgaga.
English: Nplate 125 micrograms powder for solution for injection
Estonian: Nplate 125 mikrogrammi süstelahuse pulber
English: 500 mcg/mL
Estonian: 500 µg/ml
English: • diarrhoea;
Estonian: • kõhulahtisus;
English: Thrombocytopenia is likely to reoccur upon discontinuation of treatment with romiplostim.
Estonian: Pärast ravi katkestamist romiplostiimiga on trombotsütopeenia taasteke tõenäoline.
English: • low blood platelet count (thrombocytopenia) and low blood platelet count (thrombocytopenia)
Estonian: • vereliistakute vähesus veres (trombotsütompeenia) ja vereliistakute vähesus veres
English: The subject prevalence of concurrent ITP medication use showed a trend towards a reduction over the course of the study: from 30.8% (weeks 1 to 12) to < 20.0% (weeks 13 to 240), and then 0% from week 240 to the end of the study.
Estonian: Kaasuva ITP raviga uuritavate osakaal näitas uuringu jooksul vähenemistrendi: 30,8% (nädalatel 1…12) tasemele < 20,0% (nädalatel 13…240) ja 0% alates 240. nädalast kuni uuringu lõpuni.
English: • contusion;
Estonian: • põrutus;
English: • Lift off plastic vial adapter packaging, leaving vial adapter on vial.
Estonian: • Eemaldage viaali adapteri pakend, jättes viaali adapteri viaali kluge.
English: SC
Estonian: c
English: Attach plunger rod to the pre-filled syringe of water for injections by twisting the plunger rod clockwise onto the syringe plunger, until you feel a slight resistance.
Estonian: Kinnitage kolvivars süstevett sisaldava eeltäidetud süstla külge, keerates kolvivart kellaosuti liikumise suunas süstlakolvi külge, kuni te tunnete kerget vastupanu.
English: Erythromelalgia
Estonian: Erütromelalgia
English: An additional overfill is included in each vial to ensure that 500 mcg of romiplostim can be delivered (see vial content table below).
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 500 µg romiplostiimi manustamise (vt allpool viaalide sisu tabelit).
English: Injecting the Nplate liquid
Estonian: Nplate'i lahuse süstimine
English: You may have excess Nplate left over after administering your prescribed dose.
Estonian: Pärast määratud annuse manustamist, võib Nplate'i üle jääda.
English: In adult clinical studies of treatment with romiplostim in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to AML were reported.
Estonian: Kliinilistes uuringutes täheldati MDS-iga täiskasvanud patsientide ravimisel romiplostiimiga blastsete rakkude arvu transitoorse tõusu juhte ja MDS-i progresseerumist ägedaks müeloidseks leukeemiaks.
English: Multipack: comprising 4 packs Each pack contains:
Estonian: Hulgipakend, mis sisaldab 4 üksikpakendit.
English: Following the first 4-weeks of study romiplostim maintained platelet counts ≥ 50 x 10
Estonian: Platseebokontrolliga uuringutes säilitas romiplostiim 50%...70% patsientidest pärast esimest 4 nädalat trombotsüütide arvud tasemel ≥ 50 x 10
English: Platelet counts should be assessed monthly thereafter.
Estonian: Seejärel kontrollitakse trombotsüütide arvu korra kuus.
English: EU/1/08/497/008 - 1 pack
Estonian: EU/1/08/497/008 - 1 viaaliga pakend
English: Muscle tightness Muscular weakness Shoulder pain Muscle twitching
Estonian: Artralgia Müalgia Lihasekrambid Valu jäsemetes Seljavalu Luuvalu
English: The subject prevalence of concurrent ITP medication use showed a trend towards a reduction over the course of the study: from 31.7% (weeks 1 to 12) to < 20.0% (weeks 13 to 240), and then 0% from week 240 to the end of the study.
Estonian: Kaasuva ITP raviga uuritavate osakaal näitas uuringu jooksul vähenemistrendi: 31,7% (nädalatel 1…12) tasemele < 20,0% (nädalatel 13…240) ja 0% alates 240. nädalast kuni uuringu lõpuni.
English: • fever (pyrexia);
Estonian: • palavik (püreksia);
English: (95% CI) (35%, 67%) (0%, 16%) (18%, 47%) (0%, 16%) (30%, 52%) (0%, 8%) p-value a Durable platelet response was defined as weekly platelet count ≥ 50 x 109/L for 6 or more times for study weeks 18-25 in the absence of rescue therapies any time during the treatment period.
Estonian: Trombotsütaarse vastusega patsientide arv (%) stabiilse annuse korral e usaldusvahemik) p-väärtus a Püsiv trombotsütaarne vastus oli määratletud iganädalase trombotsüütide arvuna ≥ 50 x 109/l 6 või enamal korral 18. kuni 25. uuringunädalal päästvat ravi kasutamata.
English: = 500 mcg in 1.00 mL 500 mcg/mL
Estonian: = 500 µg 1,00 ml-s 500 µg/ml
English: Nplate 250 micrograms powder for solution for injection
Estonian: Nplate 250 mikrogrammi süstelahuse pulber
English: After dissolving, a deliverable amount of 0.5 mL solution contains 250 micrograms of romiplostim (500 micrograms/mL).
Estonian: Pärast lahustamist sisaldab manustatav 0,5 ml lahust 250 mikrogrammi romiplostiimi (500 mikrogrammi/ml).
English: Nplate 125 micrograms powder for solution for injection romiplostim
Estonian: Nplate 125 mikrogrammi süstelahuse pulber romiplostimum
English: Aplastic anaemia Bone marrow failure Leucocytosis Splenomegaly Thrombocythaemia Platelet count increased
Estonian: Aplastiline aneemia Luuüdi puudulikkus Leukotsütoos Splenomegaalia Trombotsüteemia Trombotsüütide arvu tõus Ebanormaalne trombotsüütide arv
English: Nplate 500 micrograms powder for solution for injection
Estonian: Nplate 500 mikrogrammi süstelahuse pulber
English: EU/1/08/497/005 - 1 pack EU/1/08/497/006 - 4 pack
Estonian: EU/1/08/497/005 - 1 viaaliga pakend EU/1/08/497/006 - 4 viaaliga pakend
English: An additional overfill is included in each vial to ensure that 500 micrograms of romiplostim can be delivered.
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 500 mikrogrammi romiplostiimi manustamise.
English: After dissolving, a deliverable amount of 0.25 mL solution contains 125 micrograms of romiplostim (500 micrograms/mL).
Estonian: Pärast lahustamist sisaldab manustatav 0,25 ml lahust 125 mikrogrammi romiplostiimi (500 mikrogrammi/ml).
English: • chills;
Estonian: • iiveldus;
English: Each vial contains 125 mcg of romiplostim.
Estonian: Üks viaal sisaldab 125 µg romiplostiimi (romiplostimum).
English: • bruising (contusion);
Estonian: • nahapunetus (õhetus);
English: An additional overfill is included in each vial to ensure that 250 micrograms of romiplostim can be delivered.
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 250 mikrogrammi romiplostiimi manustamise.
English: An additional overfill is included in each vial to ensure that 125 mcg of romiplostim can be delivered.
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 125 µg romiplostiimi manustamise.
English: Attach vial adapter to Nplate vial by peeling off paper backing from vial adapter, keeping the vial adapter in its packaging.
Estonian: Rebige ära viaali adapteri paberkate, hoides viaali adapterit pakendis.
English: In clinical studies of treatment with romiplostim in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to AML were reported.
Estonian: Kliinilistes uuringutes täheldati MDS-iga patsientide ravimisel romiplostiimiga blastsete rakkude arvu transitoorse tõusu juhte ja MDS-i progresseerumist ägedaks müeloidseks leukeemiaks.
English: Pyrexia
Estonian: Rinorröa
English: Apply strong force while twisting to attach the safety needle onto syringe.
Estonian: Ohutu nõela süstlale kinnitamisel rakendage, keerates tugevat jõudu.
English: Nplate 250 µg powder for injection romiplostim
Estonian: Nplate 250 µg süstelahuse pulber romiplostimum s.c.
English: After dissolving, a deliverable amount of 1 mL solution contains 500 micrograms of romiplostim (500 micrograms/mL).
Estonian: Pärast lahustamist sisaldab manustatav 1 ml lahust 500 mikrogrammi romiplostiimi (500 mikrogrammi/ml).
English: If you have questions about how to inject, please ask your doctor, nurse or pharmacist for assistance.
Estonian: Kui teil on küsimusi süstimise kohta, pidage nõu oma arsti, meditsiiniõe või apteekriga.
English: Bleeding events
Estonian: Verevähi süvenemine
English: There is an increased risk of bleeding if romiplostim treatment is discontinued in the presence of anticoagulants or anti-platelet agents.
Estonian: Kui ravi romiplostiimiga katkestatakse antikoagulantide või antiagregantide foonil, suureneb verejooksu risk.
English: Self-administration of Nplate is not allowed for paediatric patients.
Estonian: Lastel ei ole lubatud ise endale Nplate manustada.
English: 625 mcg
Estonian: 625 µg
English: 9/L for most patients.
Estonian: 9/l 6-kuulise raviperioodi jooksul.
English: Each pack contains: 1 vial of 500 micrograms romiplostim.
Estonian: Üks viaal sisaldab 500 µg romiplostiimi (romiplostimum).
English: Talk to your doctor, pharmacist or nurse before using Nplate.
Estonian: Enne Nplate'i kasutamist pidage nõu oma arsti, apteekri või meditsiiniõega.
English: • ear infection;
Estonian: • kõrvapõletik;
English: Nplate 250 micrograms powder for solution for injection romiplostim
Estonian: Nplate 250 mikrogrammi süstelahuse pulber romiplostimum
English: For the storage condition after dilution of the reconstituted medicinal product see section 6.3.
Estonian: Säilitamistingimused pärast lahustatud toote lahjendamist: vt lõik 6.3.
English: EU/1/08/497/007 - 1 pack EU/1/08/497/008 - 4 pack
Estonian: EU/1/08/497/007 - 1 viaaliga pakend EU/1/08/497/008 - 4 viaaliga pakend
English: Nplate 500 µg powder for injection romiplostim
Estonian: Nplate 500 mikrogrammi süstelahuse pulber romiplostimum
English: Nplate 125 µg powder for injection romiplostim
Estonian: Nplate 125 µg süstelahuse pulber romiplostimum s.c.
English: Eczema
Estonian: Ravivead
English: For the storage condition after reconstitution of the medicinal product see section 6.3.
Estonian: Säilitamistingimused pärast ravimpreparaadi manustamiskõlblikuks muutmist vt lõik 6.3.
English: An additional overfill is included in each vial to ensure that 250 mcg of romiplostim can be delivered.
Estonian: Iga viaal sisaldab ületäitena lisakogust, mis tagab 250 µg romiplostiimi manustamise.
English: • migraine;
Estonian: • ülakõhu valu;
English: • pain;
Estonian: • valu;
English: Prepare sterile water syringe
Estonian: Steriilse süsteveega süstla ettevalmistamine
English: Powder: Mannitol (E421), sucrose, l-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Estonian: Pulber: mannitool (E421), sahharoos, L-histidiin, lahjendatud soolhape (pH korrigeerimiseks) ja polüsorbaat 20.
English: Powder: mannitol (E421), sucrose, L-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Estonian: Pulber: mannitool (E421), sahharoos, l-histidiin, lahjendatud soolhape (pH korrigeerimiseks) ja polüsorbaat 20.
English: • dizziness or a spinning sensation (vertigo);
Estonian: • pearinglus või pööritustunne (vertiigo);
English: Platelet counts should be assessed weekly until a stable platelet count
Estonian: Trombotsüütide arvu peab kontollima iga nädal, kuni on saavutatud stabiilne trombotsüütide arv (≥ 50 x 10
English: Eye pruritus
Estonian: Valk uriinis
English: Nplate 250 micrograms powder and solvent for solution for injection
Estonian: Nplate 250 mikrogrammi süstelahuse pulber ja lahusti
English: • tiredness (fatigue);
Estonian: • nahasügelus (pruritus);
English: Feeling hot
Estonian: Haiglane enesetunne Näoturse
English: Mannitol (E421), sucrose, l-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Estonian: Mannitool (E421), sahharoos, l-histidiin, lahjendatud soolhape (pH korrigeerimiseks) ja polüsorbaat 20.
English: Caution should be used when administering romiplostim to patients with known risk factors for thromboembolism including but not limited to inherited (e.g.
Estonian: Romiplostiimiga ravitud kroonilise maksahaigusega patsientidel on teatatud trombembooliajuhtudest, sh portaalveenitromboosist, ehkki põhjuslikku seost ei ole kindlaks tehtud.
English: • Do make sure the correct amount of liquid for your dose remains in the syringe.
Estonian: • Veenduge, et süstlasse jääb õige kogus lahust, mis vastab teile määratud annusele.
English: Hypoaesthesia Hypogeusia
Estonian: Hüpogeusia
English: Prepare injection needle Step 7.
Estonian: Süstlanõela ettevalmistamine Samm 7.
English: Each pack contains: 1 vial of 250 micrograms romiplostim.
Estonian: Üks viaal sisaldab 250 µg romiplostiimi (romiplostimum).
English: Diarrhoea Abdominal pain Constipation Dyspepsia
Estonian: Süstekoha verevalum Valu rindkeres Ärrituvus
English: • bruising (contusion).
Estonian: • verevalum (põrutus).
English: Rhinorrhoea Dry throat Dyspnoea Nasal congestion Painful respiration
Estonian: Oksendamine Pärakuverejooks Halb hingeõhk Düsfaagia
English: - The other ingredients are mannitol (E421), sucrose, L-histidine, hydrochloric acid (for pH adjustment) and polysorbate 20.
Estonian: - Abiained on mannitool (E421), sahharoos, L-histidiin, lahjendatud soolhape (pH korrigeerimiseks) ja polüsorbaat 20.
English: Actual body weight at initiation of treatment should always be used when calculating initial dose.
Estonian: Algannuse arvutamiseks tuleb alati kasutada tegelikku kehakaalu.
English: Malaise
Estonian: Düspepsia
English: Romiplostim
Estonian: Angioödeem
English: Nplate 500 micrograms powder and solvent for solution for injection
Estonian: Nplate 500 mikrogrammi süstelahuse pulber ja lahusti
English: Nplate 250 micrograms powder and solvent for solution for injection romiplostim
Estonian: Nplate 250 mikrogrammi süstelahuse pulber ja lahusti romiplostimum
English: Cases of thromboembolic events (TEEs), including portal vein thrombosis, have been reported in patients with chronic liver disease receiving romiplostim.
Estonian: Kliinilistes uuringutes täheldatud trombootiliste/trombemboolsete juhtude sagedus oli romiplostiimiga
English: Volume of sterile water for injection
Estonian: Steriilse süstevee mahuline kogus
English: Injection Site
Estonian: Infolehe sisukord
English: • bleeding under the skin (ecchymosis);
Estonian: • nahaalune verejooks (ekhümoos);
English: Conjunctival haemorrhage Accommodation disorder
Estonian: Süstetarvikute valmisseadmine
English: • swelling in the limbs/hands/feet;
Estonian: • jäsemete (käte või jalgade) turse;
English: Nausea
Estonian: Asteenia
English: After reconstitution, a deliverable volume of 0.25 mL solution contains 125 mcg of romiplostim (500 mcg/mL).
Estonian: Pärast lahustamist sisaldab 0,25 ml lahust 125 µg romiplostiimi (500 µg/ml).
English: After reconstitution, a deliverable volume of 0.5 mL solution contains 250 mcg of romiplostim (500 mcg/mL).
Estonian: Pärast lahustamist sisaldab 0,5 ml lahust 250 µg romiplostiimi (500 µg/ml).
English: For 250 µg kit
Estonian: 250 µg komplektile
English: Do not over tighten.
Estonian: Ärge üle keerake.
English: Upper abdominal pain***
Estonian: Ülemiste hingamisteede infektsioon Riniit***
English: Visually inspect the solution for particulate matter and discolouration before administration.
Estonian: Enne manustamist peab lahust visuaalselt kontrollima sademe esinemise ja värvuse muutuste suhtes.
English: Nplate 500 micrograms powder and solvent for solution for injection romiplostim
Estonian: Nplate 500 mikrogrammi süstelahuse pulber ja lahusti romiplostimum
English: ZIMULTI is taken as one tablet once a day, before breakfast.
Estonian: ZIMULTIt võetakse üks tablett üks kord päevas enne hommikusööki.
English: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00, Fax (44-20) 74 18 86 13 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged.
Estonian: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00, Fax (44-20) 74 18 86 13 E-mail: mail@emea.eu.int http://www.emea.eu.int©EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged.
English: The European Commission granted a marketing authorisation valid throughout the European Union for ZIMULTI to sanofi-aventis on 19 June 2006.
Estonian: Euroopa Komisjon väljastas ZIMULTI müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele sanofi-aventis 19. juunil 2006.
English: One study also looked at how this loss could be maintained during the second year.
Estonian: Ühes uuringus vaadeldi samuti, kuidas on võimalik seda vähenenud kehakaalu teise aasta jooksul säilitada.
English: These receptors are found in the nervous system, and they are part of the system the body uses to control food intake.
Estonian: Need retseptorid leiduvad inimese närvisüsteemis ning on osa süsteemist, mida organism kasutab toidu imendumise juhtimiseks.
English: The studies in smoking cessation did not show consistent results, and the effect of ZIMULTI in this area was difficult to estimate.
Estonian: Suitsetamisest loobumisega seotud uuringud ei andnud paraku ühetaolisi tulemusi ning ZIMULTI toimet selles valdkonnas oli raske hinnata.
English: Which measures are being taken to ensure the safe use of ZIMULTI?
Estonian: Milliseid meetmeid võetakse, et tagada ZIMULTI kasutamise ohutus?
English: The company will use specific databases to monitor the side effects, especially those linked to the nervous system.
Estonian: Ettevõte kasutab ZIMULTI kõrvalnähtude, eelkõige närvisüsteemiga seotud kõrvalnähtude jälgimiseks spetsiaalseid andmebaase.
English: The receptors are also found in adipocytes (fat tissue).
Estonian: Neid retseptoreid leidub ka adipotsüütides (rasvkoes).
English: It acts by blocking a specific type of receptors, the cannabinoid type 1 (CB1) receptors.
Estonian: See toimib blokeerides teatud tüüpi retseptoreid - kannabinoid-1 retseptoreid (CB-1).
English: It is available as white, teardropshaped tablets.
Estonian: Seda turustatakse valgete pisarakujuliste tablettidena.
English: The patients should also follow a reduced calorie diet and increase their level of physical activity.
Estonian: Lisaks peab patsient järgima kalorivaest dieeti ning suurendama oma kehalist aktiivsust.
English: The Committee recommended that ZIMULTI be given marketing authorisation.
Estonian: Komitee soovitas anda ZIMULTIle müügiloa.
English: The medicine also reduced the risk of regaining weight.
Estonian: Samuti alandas see ravim uuesti juurdevõtmise riski.
English: The company that makes ZIMULTI will put in place a programme to ensure that the medicine is used in patients who need it for health, rather than for cosmetic reasons, by providing educational packs for patients and doctors, and to monitor how the medicine is used.
Estonian: ZIMULTIt valmistav ettevõte rakendab programmi, et tagada ravimi kasutamine patsientidel, kes vajavad seda tervislikel mitte kosmeetilistel põhjustel - pakkudes selleks patsientidele ja arstidele teavitusmaterjale - ning et jälgida, kuidas ravimit kasutatakse.
English: Therefore, ZIMULTI is not recommended as an aid for smoking cessation
Estonian: Seetõttu ei soovitata ZIMULTIt suitsetamisest loobumise abivahendina.
English: ZIMULTI is a medicine containing the active substance rimonabant.
Estonian: ZIMULTI on ravim, mis sisaldab toimeainena rimonabanti.
English: The company decided to withdraw its application for smoking cessation.
Estonian: Suitsetamisest loobumise abivahendi osas otsustas ettevõte oma taotluse tagasi võtta.
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate oma haigusseisundi või ravi osas asjakohast lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või võtke ühendust oma arsti või apteekriga.
English: Other information about ZIMULTI:
Estonian: Muu teave ZIMULTI kohta
English: The active substance in ZIMULTI, rimonabant, is a cannabinoid receptor antagonist.
Estonian: ZIMULTI toimeaine rimonabant on kannabinoidretseptori antagonist.
English: Why has ZIMULTI been approved?
Estonian: Miks ZIMULTI heaks kiideti?
English: It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients.
Estonian: ZIMULTIt ei tohi lisaks kasutada patsientidel, kellel on raske depressioon või keda ravitakse antidepressantidega, kuna ravim võib väikese hulga patsientide seas suurendada depressiooniohtu, sealhulgas enesetapumõtete ohtu.
English: What is the risk associated with ZIMULTI?
Estonian: Millised on ZIMULTIga kaasnevad riskid?
English: ZIMULTI is used together with diet and exercise to treat adult patients:
Estonian: ZIMULTIt kasutatakse koos dieedi ja kehaliste harjutustega järgmiste täiskasvanud patsientide raviks:
English: Caution should be used when taking ZIMULTI with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics).
Estonian: Ettevaatlik tuleb olla ZIMULTI kasutamisel koos mõningate teiste ravimitega, näiteks ketokonasooli või itrakonasooliga (seentevastased ravimid), ritonaviiriga (kasutatakse HIV-nakkuse korral) või telitromütsiini või klaritromütsiiniga (antibiootikumid).
English: ZIMULTI should not be used in patients who may be hypersensitive (allergic) to rimonabant or any of the other ingredients, or in women who are breast feeding.
Estonian: ZIMULTIt ei tohi kasutada patsientidel, kes võivad olla ülitundlikud (allergilised) rimonabandi või selle ravimi mis tahes muu koostisaine suhtes, ning last rinnaga toitvatel naistel.
English: Patients who experience symptoms of depression should speak to their doctor and may need to stop treatment.
Estonian: Depressiooni sümptomitega patsiendid peavad pidama nõu arstiga ja peavad võib-olla ravi ZIMULTIga katkestama.